Compositions and methods for treatment of eye disorders
AssigneeSarcode Bioscience Inc.
InventorsThomas Gadek, John Burnier
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Claims22
A method of treating dry eye disease in a subject in need thereof comprising administering to said subject an effective amount of a lymphocyte function associated antigen-1 (LFA-1) antagonist or a pharmaceutically acceptable salt or ester thereof, wherein the LFA-1 antagonist is
- and wherein said subject has Sjogren's syndrome.
A method of treating dry eye disorder in a subject in need thereof comprising administering to an eye of said subject an effective amount of a pharmaceutical composition comprising an LFA-1 antagonist and/or its pharmaceutically acceptable salts or esters, wherein said LFA-1 antagonist is
- whereby said administering is effective in promoting tear secretion or mucin production in said eye in said subject, and wherein said subject has Sjogren's syndrome.
A method of treating dry eye disorder in a subject in need thereof comprising administering to an eye of said subject an effective amount of a pharmaceutical composition comprising an LFA-1 antagonist and/or its pharmaceutically acceptable salts or esters, wherein said LFA-1 antagonist is
- wherein said subject has Sjogren's syndrome, and wherein said administering comprises administering said compound in liquid drops.
Dependencies are inferred from the claim text.